The presence of financial conflicts of interest in clinical practice guidelines (CPGs) may affect the objectivity of these documents. Although the National Academy of Medicine has created policies to limit industry influence on the development of CPGs, guidelines rarely adhere to these policies.1 Moreover, CPG authors may have undeclared financial conflicts of interest.2 We hypothesized that undeclared industry payments would be highly prevalent among authors of CPGs related to high-revenue medications, and we quantified the presence and extent of these payments.
Identify all potential conflicts of interest that might be relevant to your comment.
Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.
Err on the side of full disclosure.
If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.
Not all submitted comments are published. Please see our commenting policy for details.
Khan R, Scaffidi MA, Rumman A, Grindal AW, Plener IS, Grover SC. Prevalence of Financial Conflicts of Interest Among Authors of Clinical Guidelines Related to High-Revenue Medications. JAMA Intern Med. 2018;178(12):1712–1715. doi:10.1001/jamainternmed.2018.5106
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: